Amuvatinib (MP-470), an oral dual inhibitor of mutant kinases and DNA repair: Final results from a 100-patient, 5-arm phase Ib trial in combination with five standard of care (SOC) anticancer regimens.

@article{Sankhala2011AmuvatinibA,
  title={Amuvatinib (MP-470), an oral dual inhibitor of mutant kinases and DNA repair: Final results from a 100-patient, 5-arm phase Ib trial in combination with five standard of care (SOC) anticancer regimens.},
  author={Kamalesh K Sankhala and Anthony William Tolcher and Monica M. Mita and Michael S Gordon and Lee S. Rosen and Kyriakos P. Papadopoulos and Amita Patnaik and Ronald L Drengler and Alain C. Mita and John Sarantopoulos and Robert G. Bristow and Gil Fine and Gavin S Choy and Mohammad Azab},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={3074}
}
3074 Background: Amuvatinib is an oral multi-targeted TKI which inhibits the mutant forms of c-kit, and PDGFRα. It also disrupts DNA repair probably through suppression of Homologous Recombination protein Rad51. METHODS Adults with cancer diagnosis appropriate for one of the 5 SOC regimens to be studied received amuvatinib (dry-powder capsules) in combination with SOC. The 5 SOC regimens were: paclitaxel/carboplatin (PC), carboplatin/etoposide (CE), topotecan (T), docetaxel (D), and erlotinib… CONTINUE READING